EZRA
Reliance Global Group, Inc. (EZRA) Risks & Opportunities Analysis (2026)
No material changes this month.
Risks
Negative net debt and 19.6x interest coverage indicate limited refinancing pressure, reducing peer-relative balance-sheet risk versus more levered competitors in the same market.
A 148-day cash conversion cycle reflects working-capital intensity, which can constrain liquidity and growth flexibility more than peers with faster cash turns.
Days payable outstanding of -119.9 suggests structurally unfavorable supplier terms, increasing funding needs and margin sensitivity versus peers with stronger purchasing power.
Current and quick ratios of 1.63 provide a liquidity buffer, but the absence of reported FCF margin leaves peer-relative cash durability less visible than for cash-generative rivals.
Opportunities
Net cash positioning and strong interest coverage create capacity to absorb volatility, supporting more resilient execution than highly indebted peers during demand swings.
A current ratio of 1.63 and quick ratio of 1.63 indicate adequate near-term liquidity, which can support working-capital needs better than tighter-liquidity peers.
Low debt-to-equity of 0.79 leaves room for balance-sheet flexibility, improving relative positioning versus peers that may need to prioritize deleveraging over growth.
If working-capital efficiency improves from the current 148-day cycle, cash release could enhance growth funding more quickly than peers with similar operating profiles.
Overall Score
EZRA’s net-cash balance sheet and solid coverage metrics support strong peer-relative resilience, while working-capital intensity and supplier-term pressure remain the main constraints.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Reliance Global Group, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
